32 news items
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, Sonder, QuidelOrtho, and Perion Innovations and Encourages Investors to Contact the Firm
OCGN
PERI
3 Jun 24
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
OCGN
31 May 24
that improve health and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Ocugen, Sonder, and QuidelOrtho Innovations and Encourages Investors to Contact the Firm
HRT
OCGN
29 May 24
Ocugen to Present at BIO International Convention 2024
OCGN
29 May 24
for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
OCGN
28 May 24
assurance. Index innovation is driven by client needs and customer partnerships, allowing FTSE Russell to continually enhance the breadth, depth
93ay6jo6
HRT
OCGN
25 May 24
z49r4l11utmxyx
HRT
OCGN
21 May 24
vu8zz1l6p2ks97gkfn8g3uxq9as38cn5z3a2kmla4bbdp0ae50j64ok7 g05
OCGN
20 May 24
the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual
pouxwk6x7exxyozyje 8qrm2j4
CKPT
HRT
OCGN
16 May 24
t3rj57d1cju7md743lzdmwi wjn
OCGN
15 May 24
' lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene
dkwzgtgau63ddjegmety35psti9ar 6hholnjfp43iex2
CKPT
HRT
OCGN
12 May 24
255oi512yeeix8vcec
OCGN
10 May 24
the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual
o2u29vigjkvpzc3ktqesozr8f8 aoqz4wscx2
OCGN
10 May 24
hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness
r9af1ch67eqg7 u76qyso1v
CKPT
HRT
OCGN
7 May 24
8wvu u62yjwk1
OCGN
3 May 24
on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our
yuc98cux3ekfqgmdhmlwt28q8ga0ew65djdp7gn17f9f7
OCGN
2 May 24
are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human
iikn469vf5hfo7gg dz1uwm0
DD
DYAI
HCA
29 Apr 24
—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3
aceq6tsu498qg9tlv573 9ovc8t88ymxlyh887jsc4x2zp
OCGN
29 Apr 24
—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.
xfp338t22bup75qwu850lugmq3vra4rrb5e57dwdq9ccc64fxa
OCGN
29 Apr 24
of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3
ye07 zz1rc1s
OCGN
26 Apr 24
that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT